Please assess the completion status of the following clinical trial:

Trial Title: EXCimEr Laser for Long lENgTh Lesions in Below-The-Knee Arteries Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The treatment vessel is DeNovo~* Stenotic (\>50%) or occlusive atherosclerotic disease of infrapopliteal artery(s)~* Length of target lesion is \> 50 mm~* Reference target vessel diameter between 2-4.0 mm by visual assessment~* Documented Rutherford Class 4 or 5 symptomatic critical limb ischemia~* The patient must be \>18 years of age~* Life-expectancy of more than 12 months~* The patient has no child bearing potential or negative serum pregnancy test within 7 days of the index procedure~* The patient must be willing and able to return to the appropriate follow-up times for the duration of the study~* The patient must provide written patient informed consent that is approved by the ethics committee~* Anatomic Inclusion Criteria~  * All inflow lesions successfully (\<30 residual stenosis) treated prior to target lesion treatment during same procedure or according standard of care without unresolved complications~ * At least one angiographically visible target at the ankle for establishment of straight line flow.~Exclusion Criteria:~* Patient refusing treatment~* The target vessel segment diameter is not suitable for available catheter design.~* Unsuccessfully treated endovascular or bypass( \>30% residual stenosis) proximal ( iliac, SFA, popliteal) inflow limiting arterial/graft stenosis~* Lesion lies within or adjacent to an aneurysm~* The patient has a known allergy to heparin, Aspirin or other antiaggregant therapies or a bleeding diatheses or is unable, or unwilling, to tolerate such therapies.~* The patient has a history of prior life-threatening contrast media reaction.~* The patient is currently enrolled in another investigational device or drug trial.~* The patient is currently breast-feeding, pregnant or intends to become pregnant.~* The patient is unable to provide informed consent~* The patient has end stage renal disease (currently on any form of dialysis)~* Known Left Ventricular Ejection Fraction \< 35%~* The patient has had an MI within 30 days prior to enrollment~* The patient has had a CVA within 90 days prior to enrollment~* Serum Creatinine \> 150 µmol~* The patient has a previous bypass in the target limb~* The patient has a current systemic infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): CLI patients receiving excimer laser recanalisation for the treatment of long infrapopliteal lesions

Based on this trial design, predict the completion outcome and termination type (if applicable).